13.33
price down icon5.46%   -0.77
after-market After Hours: 13.33
loading
Inhibrx Biosciences Inc stock is traded at $13.33, with a volume of 220.45K. It is down -5.46% in the last 24 hours and down -1.84% over the past month.
See More
Previous Close:
$14.10
Open:
$14.1
24h Volume:
220.45K
Relative Volume:
2.35
Market Cap:
$192.96M
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.1123
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
-6.91%
1M Performance:
-1.84%
6M Performance:
-10.42%
1Y Performance:
-62.00%
1-Day Range:
Value
$13.32
$14.10
1-Week Range:
Value
$13.32
$14.64
52-Week Range:
Value
$10.80
$35.42

Inhibrx Biosciences Inc Stock (INBX) Company Profile

Name
Name
Inhibrx Biosciences Inc
Name
Phone
(858) 795-4220
Name
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-05-24
Name
Latest SEC Filings
Name
INBX's Discussions on Twitter

Compare INBX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INBX
Inhibrx Biosciences Inc
13.33 192.96M 1.80M 1.76B -149.23M 118.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-23-24 Initiated JMP Securities Mkt Perform
Jan-23-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-16-22 Initiated SMBC Nikko Outperform
Sep-21-21 Initiated JMP Securities Mkt Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Sep-14-20 Initiated Credit Suisse Outperform
Sep-14-20 Initiated Evercore ISI Outperform
View All

Inhibrx Biosciences Inc Stock (INBX) Latest News

pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire

Apr 01, 2025
pulisher
Mar 26, 2025

How the (INBX) price action is used to our Advantage - Stock Traders Daily

Mar 26, 2025
pulisher
Mar 18, 2025

JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India

Mar 18, 2025
pulisher
Mar 17, 2025

Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit - Stock Titan

Mar 17, 2025
pulisher
Mar 15, 2025

Long Term Trading Analysis for (INBX) - Stock Traders Daily

Mar 15, 2025
pulisher
Mar 04, 2025

When (INBX) Moves Investors should Listen - Stock Traders Daily

Mar 04, 2025
pulisher
Feb 17, 2025

A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News

Feb 17, 2025
pulisher
Feb 11, 2025

When the Price of (INBX) Talks, People Listen - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com

Feb 05, 2025
pulisher
Jan 31, 2025

(INBX) Trading Signals - Stock Traders Daily

Jan 31, 2025
pulisher
Jan 23, 2025

Inhibrx reports promising ozekibart trial results - MSN

Jan 23, 2025
pulisher
Jan 23, 2025

Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN

Jan 23, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - Stock Titan

Jan 21, 2025
pulisher
Jan 20, 2025

How to Take Advantage of moves in (INBX) - Stock Traders Daily

Jan 20, 2025
pulisher
Jan 14, 2025

Inhibrx Biosciences enters $150M loan facility - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News

Jan 14, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - Stock Titan

Jan 13, 2025
pulisher
Jan 10, 2025

(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jan 10, 2025
pulisher
Dec 30, 2024

How To Trade (INBX) - Stock Traders Daily

Dec 30, 2024
pulisher
Dec 17, 2024

Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India

Dec 17, 2024
pulisher
Dec 09, 2024

(INBX) Trading Report - Stock Traders Daily

Dec 09, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com

Dec 05, 2024
pulisher
Dec 02, 2024

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights

Dec 02, 2024
pulisher
Nov 22, 2024

Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria

Nov 22, 2024
pulisher
Nov 18, 2024

Trend Tracker for (INBX) - Stock Traders Daily

Nov 18, 2024
pulisher
Nov 17, 2024

The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance

Nov 17, 2024
pulisher
Nov 17, 2024

institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St

Nov 17, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 14, 2024
pulisher
Nov 12, 2024

Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 09, 2024

Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com

Nov 09, 2024
pulisher
Nov 07, 2024

Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle

Nov 07, 2024
pulisher
Nov 05, 2024

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha

Nov 05, 2024
pulisher
Nov 04, 2024

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times

Nov 04, 2024
pulisher
Oct 25, 2024

James Sabry on industry-shaping changes in innovation and deal-making - BioCentury

Oct 25, 2024

Inhibrx Biosciences Inc Stock (INBX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):